Recent studies have converged on the overlap of GLP|GIP|glucagon receptor agonist therapies and DA neurotransmission. While GCGR activators are increasingly employed for managing type 2 T2DM, their potential consequences on motivation circuits, specifically mediated by dopaminergic networks, are gaining considerable attention. This paper presents a